Avoid using harsh solvents or those with extreme pH unless specifically dictated by your experimental protocol and validated for GHK-Cu stability
Peptides work best as part of a comprehensive approach
The honest position is that the systemic pharmacology of injectable GHK-Cu is reasoned rather than measured, and any number one might attach to a dose would therefore be extrapolation resting on assumptions the data have not tested
The authors reported greater reductions in body weight and in glycated hemoglobin in the combination arm relative to either monotherapy arm within the trial, with gastrointestinal events again the most frequently reported category
Initiated biologics included in this analysis were adalimumab, certolizumab, etanercept, infliximab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, tildrakizumab, and available biosimilars (adalimumab, etanercept, and infliximab)